Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

Introduction Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Job P van Kooten, Jacobus W A Burger, Cornelis Verhoef, Joachim G J V Aerts, Eva V E Madsen, Alexandra R M Brandt-Kerkhof, Stijn L W Koolen, Ron H J Mathijssen, Michelle V Dietz, Niels A D Guchelaar
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2022-06-01
coleção:	BMJ Open
Acesso em linha:	https://bmjopen.bmj.com/content/12/6/e062907.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!